- |||||||||| ACE1831 / Acepodia
A Phase 1, Open-Label, Multicenter Study of Treatment with ACE1831, Comprised of Allogeneic Gamma Delta T Cells Conjugated to an Anti-CD-20 Antibody, in Patients (Pts) with B-Cell Relapsed/Refractory Non-Hodgkin's Lymphoma (R/R NHL) () - Dec 7, 2024 - Abstract #ASH2024ASH_9279;
P1
Anti-drug antibody responses to ACE1831 were monitored by flow cytometry analysis in four pts during the DLT period with Day -5 levels as baseline and there were no increases of anti-ACE1831 antibodies observed.ConclusionsPreliminary data in 5 pts showed no DLTs, ACE1831-related SAEs, as well as no CRS, ICANS, or GvHD in single dose of 0.3B cells in 5 pts. Dose escalation will continue including 0.6 and 1B cells, with updated clinical data to be provided.Clinical trial identificationNCT05653271
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Journal: A Novel Allogeneic Rituximab-Conjugated Gamma Delta T Cell Therapy for the Treatment of Relapsed/Refractory B-Cell Lymphoma. (Pubmed Central) - Oct 14, 2023
Intriguingly, the antigen recognition of the ACC-linked antibody/receptor complex stimulated NFAT activation and contributed to ACE1831-mediated cytotoxicity against CD20-expressing cancer cells. This study elucidates the role of the ACC-linked antibody/receptor complex in cytotoxicity and supports the potential of ACE1831 as an off-the-shelf ??2 cell therapy against relapsed/refractory B-cell lymphoma.
- |||||||||| ACE1831 / Acepodia
Enrollment open: ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies (clinicaltrials.gov) - Jan 26, 2023
P1, N=42, Recruiting,
This study elucidates the role of the ACC-linked antibody/receptor complex in cytotoxicity and supports the potential of ACE1831 as an off-the-shelf ??2 cell therapy against relapsed/refractory B-cell lymphoma. Not yet recruiting --> Recruiting
|
